These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 23770429)

  • 1. The interaction of nifedipine with selected cyclodextrins and the subsequent solubility-permeability trade-off.
    Beig A; Miller JM; Dahan A
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1293-9. PubMed ID: 23770429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toward Successful Cyclodextrin Based Solubility-Enabling Formulations for Oral Delivery of Lipophilic Drugs: Solubility-Permeability Trade-Off, Biorelevant Dissolution, and the Unstirred Water Layer.
    Fine-Shamir N; Beig A; Zur M; Lindley D; Miller JM; Dahan A
    Mol Pharm; 2017 Jun; 14(6):2138-2146. PubMed ID: 28505451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of captisol (SBE7-β-CD) in oral solubility-enabling formulations: Comparison to HPβCD and the solubility-permeability interplay.
    Beig A; Agbaria R; Dahan A
    Eur J Pharm Sci; 2015 Sep; 77():73-8. PubMed ID: 26006306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: mechanistic modeling and application to progesterone.
    Dahan A; Miller JM; Hoffman A; Amidon GE; Amidon GL
    J Pharm Sci; 2010 Jun; 99(6):2739-49. PubMed ID: 20039391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral delivery of lipophilic drugs: the tradeoff between solubility increase and permeability decrease when using cyclodextrin-based formulations.
    Beig A; Agbaria R; Dahan A
    PLoS One; 2013; 8(7):e68237. PubMed ID: 23874557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A win-win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability.
    Miller JM; Beig A; Carr RA; Spence JK; Dahan A
    Mol Pharm; 2012 Jul; 9(7):2009-16. PubMed ID: 22632106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting the solubility-permeability interplay when using cyclodextrins in solubility-enabling formulations: model validation.
    Miller JM; Dahan A
    Int J Pharm; 2012 Jul; 430(1-2):388-91. PubMed ID: 22465550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Solubility-Permeability Trade-Off of Progesterone With Cyclodextrins Under Physiological Conditions: Experimental Observations and Computer Simulations.
    Sun L; Zhang B; Sun J
    J Pharm Sci; 2018 Jan; 107(1):488-494. PubMed ID: 29031956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The solubility-permeability interplay when using cosolvents for solubilization: revising the way we use solubility-enabling formulations.
    Miller JM; Beig A; Carr RA; Webster GK; Dahan A
    Mol Pharm; 2012 Mar; 9(3):581-90. PubMed ID: 22280478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Head-To-Head Comparison of Different Solubility-Enabling Formulations of Etoposide and Their Consequent Solubility-Permeability Interplay.
    Beig A; Miller JM; Lindley D; Carr RA; Zocharski P; Agbaria R; Dahan A
    J Pharm Sci; 2015 Sep; 104(9):2941-7. PubMed ID: 25989509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The twofold advantage of the amorphous form as an oral drug delivery practice for lipophilic compounds: increased apparent solubility and drug flux through the intestinal membrane.
    Dahan A; Beig A; Ioffe-Dahan V; Agbaria R; Miller JM
    AAPS J; 2013 Apr; 15(2):347-53. PubMed ID: 23242514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling the influence of cyclodextrins on oral absorption of low solubility drugs: II. Experimental validation.
    Gamsiz ED; Miller L; Thombre AG; Ahmed I; Carrier RL
    Biotechnol Bioeng; 2010 Feb; 105(2):421-30. PubMed ID: 19725043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formulation of rifampicin-cyclodextrin complexes for lung nebulization.
    Tewes F; Brillault J; Couet W; Olivier JC
    J Control Release; 2008 Jul; 129(2):93-9. PubMed ID: 18514353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The solubility-permeability interplay: mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation.
    Miller JM; Beig A; Krieg BJ; Carr RA; Borchardt TB; Amidon GE; Amidon GL; Dahan A
    Mol Pharm; 2011 Oct; 8(5):1848-56. PubMed ID: 21800883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of cyclodextrins as solubilizing agents for simvastatin: effect of hydroxypropyl-β-cyclodextrin on lactone/hydroxyacid aqueous equilibrium.
    Ungaro F; Giovino C; Catanzano O; Miro A; Mele A; Quaglia F; La Rotonda MI
    Int J Pharm; 2011 Feb; 404(1-2):49-56. PubMed ID: 21056648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-assembly of cyclodextrin complexes: aggregation of hydrocortisone/cyclodextrin complexes.
    Messner M; Kurkov SV; Brewster ME; Jansook P; Loftsson T
    Int J Pharm; 2011 Apr; 407(1-2):174-83. PubMed ID: 21237259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An ocular drug delivery system containing zinc diethyldithiocarbamate and HPbetaCD inclusion complex--corneal permeability, anti-cataract effects and mechanism studies.
    Wang S; Li D; Ito Y; Liu X; Zhang J; Wu C
    J Pharm Pharmacol; 2004 Oct; 56(10):1251-7. PubMed ID: 15482639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling the effect of selected cyclodextrins on nifedipine solubility.
    Agatonovic-Kustrin S; Morton DW; Worthington MS; Glass BD
    Curr Drug Discov Technol; 2011 Jun; 8(2):146-54. PubMed ID: 21091429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inclusion complex and nanoclusters of cyclodextrin to increase the solubility and efficacy of albendazole.
    Pacheco PA; Rodrigues LNC; Ferreira JFS; Gomes ACP; Veríssimo CJ; Louvandini H; Costa RLD; Katiki LM
    Parasitol Res; 2018 Mar; 117(3):705-712. PubMed ID: 29327323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study of the interaction between S(--) bupivacaine and 2-hydroxypropyl-beta-cyclodextrin.
    Moraes CM; Abrami P; de Paula E; Braga AF; Fraceto LF
    Int J Pharm; 2007 Feb; 331(1):99-106. PubMed ID: 17071028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.